ASCO 2022: Focus on Metastatic Breast Cancer
Advertisement
Investigational Treatment Combo Produces Responses in HER2-Positive Metastatic Breast Cancer
Kerri FitzgeraldASCO 2022 | March 26, 2025
Pyrotinib, a second-generation, irreversible anti-human epidermal growth factor receptor 2 (HER2) tyrosine kinase ...
Read More
These Factors Predict Survival in Patients With HER2-Positive Breast Cancer and Brain Metastases
Kerri FitzgeraldASCO 2022 | March 26, 2025
Research presented at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting indicated that the following ...
Read More
Addition of Ribociclib to Endocrine Therapy Improves Survival in Metastatic Breast Cancer
Kerri FitzgeraldASCO 2022 | March 26, 2025
The phase II MAINTAIN trial evaluated the efficacy of adding ribociclib to endocrine therapy in patients with hormone ...
Read More
“Practice-Changing” Results Seen With Targeted Therapy in HER2-Low Metastatic Breast Cancer
Kerri FitzgeraldASCO 2022 | March 26, 2025
Results of the DESTINY-Breast04 study, presented at the 2022 American Society of Clinical Oncology (ASCO) Annual ...
Read More
Advertisement
Advertisement
Advertisement
Latest News

Brensocatib Shows Positive Results for Managing Bronchiectasis Symptoms

April 30, 2025

Kidney Stones With Chlorthalidone Versus Hydrochlorothiazide

April 30, 2025

Measles in America: An Ongoing Problem

April 30, 2025

  • 630 Madison Ave.

    Manalapan, NJ 07726

    • About

    About Us

    Editorial Policy

    Advertising

    Connect

    Contact Us

    eNewsletters

    Contribute

    Career Center

    Our Network

    MashupMD

    Blood Cancers Today

    Cancer Nursing Today

    GU Oncology Now

    Urban Health Today

    © 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.

    Terms of Use | Privacy Policy |